Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Onconetix Inc (ONCO)

Onconetix Inc (ONCO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Oncopeptides Chief Financial Officer Holger Lembrer takes office today PR Newswire - Wed Jan 18, 2023

/PRNewswire/ -- Oncopeptides AB (publ.) (NASDAQ Stockholm: ONCO), a biotech company focused on commercialization, research, and development of therapies for...

ONCO : 0.1235 (+9.29%)
Oncopeptides appoints Holger Lembrer as Chief Financial Officer PR Newswire - Wed Jan 11, 2023

/PRNewswire/ -- Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...

ONCO : 0.1235 (+9.29%)
Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer PR Newswire - Wed Jan 4, 2023

/PRNewswire/ -- Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...

ONCO : 0.1235 (+9.29%)
Oncopeptides has announced the Nomination Committee PR Newswire - Thu Dec 22, 2022

/PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). According to the principles for the appointment of the Nomination Committee in Oncopeptides AB...

ONCO : 0.1235 (+9.29%)
Oncopeptides presents new scientific data at the Annual American Society of Hematology Meeting ASH PR Newswire - Mon Dec 12, 2022

/PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...

ONCO : 0.1235 (+9.29%)
Oncopeptides provides update on Pepaxto US marketing authorization PR Newswire - Wed Dec 7, 2022

/PRNewswire/ -- Oncopeptides AB (publ) (NASDAQ Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat...

ONCO : 0.1235 (+9.29%)
Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank PR Newswire - Fri Nov 25, 2022

/PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...

ONCO : 0.1235 (+9.29%)
Oncopeptides' Pepaxti has been granted marketing authorization in the UK PR Newswire - Fri Nov 11, 2022

/PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...

ONCO : 0.1235 (+9.29%)
Oncopeptides publishes Q3 report 2022 PR Newswire - Wed Nov 9, 2022

/PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...

ONCO : 0.1235 (+9.29%)
Oncopeptides announces the market potential for Pepaxti in Europe PR Newswire - Wed Nov 9, 2022

/PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...

ONCO : 0.1235 (+9.29%)

Barchart Exclusives

Tesla Stock Put Options Are Still Highly Priced - Ideal for Shareholders to Sell Short for Income Barchart - 55 minutes ago
Tesla Inc. put options in near-term expiry periods are still at high premium levels, even after TSLA stock has rebounded. This is ideal for existing shareholders to sell short to gain extra income. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot